Open access · US-GOV via ClinicalTrials.gov Clinical trial

Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects

Authors not listed

The University of Texas Health Science Center at San Antonio · 2016

Dysbiosis Human Randomized controlled trial

Abstract

This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarbose in non-diabetic elderly humans, and iii) determine whether the effects of acarbose on the microbiome likely play a role in its enhancement of longevity and/or healthy aging. These are essential initial steps for translating acarbose into an anti-aging human therapy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-31 MST

Cite this

APA

Anonymous. (2016). Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects. <em>The University of Texas Health Science Center at San Antonio</em>. https://clinicaltrials.gov/study/NCT02865499

Vancouver

Anonymous. Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects. The University of Texas Health Science Center at San Antonio. 2016.

BibTeX

@misc{anon2016Acarbo, title = {Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects}, author = {Anonymous}, journal = {The University of Texas Health Science Center at San Antonio}, year = {2016}, }